The study site monitor will regularly visit the study sites to ensure that the study is conducted according to the protocol and GCP principles. 7.0 STUDY EVALUATIONS 7.1 Schedule of Study Evaluations Study evaluations are summar ized in Table 3 and described in Sections 1.1 through 7.6. Heat Biologics Protocol No. HS130 -001 A Phase I Study of HS -130 in combination with HS-110 in patients with solid tumors HS130- 001 36 of 60 Version 2.0 - 11 Feb 2020 Confidential - Entire Page Table 3: Schedule of Assessments Pre- treatment Cycle 1 (± 2 days)p Cycle 2 (± 2 days)p Cycle 3 and beyond (± 2 days)p 30-day safety follow up visit (±3 days )m Post - treatment Follow -up (±1 week)n Survival Follow -up (±2 week)o Day 1 Day 8 Day 1 Day 8 Day 1 Informed consent Xa Medical history Xa Physical exam Xb Xb X X X X X Weight Xb Xb X X X X X Vital signsc Xb X X X X X X ECGd Xa X X X X ECOG performance status Xb Xb X X X X X Tumor measuremente Xa Xe Xn Hematologyf Xb Xb X X X Blood chemistryg Xb Xb X X X Pregnancy test h Xb Blood Sample for Immune Response Labsi Xi Xi Xi Xi X Blood sample for cytokines/chemokinesj Xj Xj Xj Biopsyk Xa Xk HS-130 and HS -110 administrationl X X X Concomitant medications /Treatment Xa Throughout Study X X Xo Adverse events Throughout Study X X Survival Status Xo Heat Biologics Protocol No. HS130 -001 A Phase I Study of HS -130 in combination with HS-110 in patients with solid tumors HS130- 001 37 of 60 Version 2.0 - 11 Feb 2020 Confidential - Entire Page a: Within 28 days prior to treatment. b: Within 7 days prior to treatment.